What is Zacks Research’s Forecast for ORMP FY2026 Earnings?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) – Investment analysts at Zacks Research increased their FY2026 earnings estimates for shares of Oramed Pharmaceuticals in a research note issued to investors on Thursday, June 18th. Zacks Research analyst M. Marin now anticipates that the biotechnology company will post earnings per share of $1.24 for the year, up from their previous forecast of $0.71. The consensus estimate for Oramed Pharmaceuticals’ current full-year earnings is $0.71 per share.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings results on Friday, March 27th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02.

Separately, Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Oramed Pharmaceuticals Price Performance

NASDAQ:ORMP opened at $4.30 on Thursday. The company has a market capitalization of $176.00 million, a P/E ratio of 1.66 and a beta of 1.26. The business has a fifty day simple moving average of $3.99 and a two-hundred day simple moving average of $3.55. Oramed Pharmaceuticals has a 1 year low of $1.98 and a 1 year high of $5.01.

Institutional Trading of Oramed Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Kathmere Capital Management LLC purchased a new position in Oramed Pharmaceuticals in the 1st quarter valued at approximately $51,000. OMERS ADMINISTRATION Corp bought a new stake in Oramed Pharmaceuticals during the 1st quarter valued at $63,000. Redwood Family Wealth LLC purchased a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth $66,000. XTX Topco Ltd boosted its holdings in shares of Oramed Pharmaceuticals by 59.9% in the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 14,297 shares during the period. Finally, Quadrature Capital Ltd bought a new position in shares of Oramed Pharmaceuticals in the fourth quarter worth $119,000. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.